Literature DB >> 15168351

Animal models of pheochromocytoma.

A S Tischler1, J F Powers, J Alroy.   

Abstract

Pheochromocytomas are neuroendocrine tumors of adrenal chromaffin cells. They are rare in all species except rats but occur with increased frequency in several human familial tumor syndromes. Concurrence of pheochromocytoma with other tumors sometimes parallels these human syndromes in rats, bovines, horses and dogs but a shared genetic basis for human and spontaneously occurring animal pheochromocytomas has thus far not been established. Pheochromocytomas are inducible in rats by a variety of non-genotoxic substances that may act indirectly by stimulating chromaffin cell proliferation. They are not known to be similarly inducible in other species but arise with increased frequency in transgenic and knockout mice that to varying degrees recapitulate human tumor syndromes. Preliminary evidence suggests that homologous somatic genetic changes might contribute to pheochromocytoma development in humans and some mouse models. The nerve growth factor-responsive PC12 cell line, established from a rat pheochromocytoma, has for almost 30 years served as a research tool for many aspects of neurobiology involving normal and neoplastic conditions. Recently developed pheochromocytoma cell lines from neurofibromatosis knockout mice supplement the PC12 line and have generated additional applications. Advantages of the mouse lines include expression of substantial levels of the epinephrine-synthesizing enzyme, phenylethanolamine N-methyltransferase and expression of high levels of the receptor tyrosine kinase, Ret, which is characteristic of sporadic and familial human pheochromocytomas but not of PC12 cells. Disadvantages include an apparently less stable phenotype. It is difficult to establish pheochromocytoma cell lines from any species, although the tumor cells persist in culture for many months. Understanding of factors that permit pheochromocytoma cells to proliferate might itself provide important insights for tumor biology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168351     DOI: 10.14670/HH-19.883

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  17 in total

1.  Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice.

Authors:  James F Powers; Karel Pacak; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

2.  Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging.

Authors:  Alessio Giubellino; Girma M Woldemichael; Carole Sourbier; Martin J Lizak; James F Powers; Arthur S Tischler; Karel Pacak
Journal:  Cancer Lett       Date:  2011-10-20       Impact factor: 8.679

3.  Effect of tricyclodecan-9-yl potassium xanthate (D609) on phospholipid metabolism and cell death during oxygen-glucose deprivation in PC12 cells.

Authors:  E C Larsen; J F Hatcher; R M Adibhatla
Journal:  Neuroscience       Date:  2007-04-16       Impact factor: 3.590

4.  Comparative studies of PC12 and mouse pheochromocytoma-derived rodent cell lines as models for the study of neuroendocrine systems.

Authors:  Darcelle N Dixon; Rhonda A Loxley; Anna Barron; Susannah Cleary; Jacqueline K Phillips
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jul-Aug       Impact factor: 2.416

5.  MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice.

Authors:  Shoichiro Ohta; Edwin W Lai; John C Morris; Douglas A Bakan; Brenda Klaunberg; Susannah Cleary; James F Powers; Arthur S Tischler; Mones Abu-Asab; Daniel Schimel; Karel Pacak
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

6.  Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus).

Authors:  A D Miller; K Masek-Hammerman; K Dalecki; K G Mansfield; S V Westmoreland
Journal:  Vet Pathol       Date:  2009-07-15       Impact factor: 2.221

7.  Adrenergic differentiation and Ret expression in rat pheochromocytomas.

Authors:  James F Powers; Kristen L Picard; Abraham Nyska; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

8.  Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.

Authors:  Alessio Giubellino; Petra Bullova; Svenja Nölting; Hana Turkova; James F Powers; Qingsong Liu; Sylvie Guichard; Arthur S Tischler; Ashley B Grossman; Karel Pacak
Journal:  Endocrinology       Date:  2013-01-10       Impact factor: 4.736

9.  Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature.

Authors:  Lucia Martiniova; Edwin W Lai; Abdel G Elkahloun; Mones Abu-Asab; Andrea Wickremasinghe; Daniel C Solis; Shiromi M Perera; Thanh-Truc Huynh; Irina A Lubensky; Arthur S Tischler; Richard Kvetnansky; Salvatore Alesci; John C Morris; Karel Pacak
Journal:  Clin Exp Metastasis       Date:  2009-01-25       Impact factor: 5.150

10.  Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.

Authors:  Alessio Giubellino; Carole Sourbier; Min-Jung Lee; Brad Scroggins; Petra Bullova; Michael Landau; Weiwen Ying; Len Neckers; Jane B Trepel; Karel Pacak
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.